Drug Profile
Acyclic oxazolylrifamycin
Latest Information Update: 30 May 2001
Price :
$50
*
At a glance
- Originator Novartis
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 17 Jun 1998 No-Development-Reported for Hyperlipidaemia in Switzerland (Unknown route)
- 05 Oct 1994 Preclinical development for Hyperlipidaemia in Switzerland (Unknown route)